查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854806

伴侣动物疫苗市场（依动物种类、疫苗类型、给药途径及通路划分）－全球预测，2025-2032年

Companion Animal Vaccine Market by Animal Type, Vaccine Type, Route Of Administration, Distribution Channel - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，伴侣动物疫苗市场规模将达到 95.4 亿美元，复合年增长率为 8.47%。

关键市场统计数据
基准年 2024 49.7亿美元
预计年份：2025年 53.9亿美元
预测年份 2032 95.4亿美元
复合年增长率 (%) 8.47%

全面介绍不断发展的伴侣动物疫苗领域：科学创新与饲主期望和临床实践的转变相融合

伴侣动物疫苗领域正处于科学进步、饲主不断变化的需求以及不断发展的临床实践的交汇点。如今，预防保健理念和治疗方法创新共同塑造犬猫疫苗接种策略，并影响诊所的工作流程和供应链动态。兽医相关人员越来越多地将诊断筛检、个人化疫苗通讯协定和基于风险的建议融入日常工作中，这迫使生产商和经销商重新思考产品系列和沟通策略。

随着消费者对动物健康的意识不断增强，宠物饲主对疫苗安全性和效用的要求也越来越高，他们需要更明确的证据。同时，数位化管道加速了人们获取教育内容和购买管道的进程。此外，mRNA和重组系统等平台技术的研究突破正在拓展抗原标靶的范围，并提升疫苗的免疫抗原性和生产效率。这些发展迫使疫苗生产商在现有灭活疫苗和减毒活病毒疫苗的基础上，增加对新一代疫苗的投资。

此外，给药途径和分销环境也会影响产品设计和商业策略。鼻腔和口腔黏膜疫苗的接受度与肌肉注射和皮下注射疫苗有所不同，而包括网路药局和生产商网站在内的线上管道正在改变消费者的购买行为。这些动态共同要求产品开发、监管策略和市场开发采取整合策略，使科学机会与实际应用路径相符。

本文详细概述了影响伴侣动物疫苗研发、交付和推广应用的主要技术、行为和临床变化。

伴侣动物疫苗领域正经历着变革性的转变，其驱动力包括技术创新、消费者行为的改变以及监管和临床模式的演进。疫苗平台（尤其是mRNA和重组技术）的开发，开启了新的可能性，包括靶向免疫策略、更短的研发週期以及可适应新出现的疾病威胁的生产过程。这些科学进步正在重新定义产品蓝图，并迫使现有製造商重新评估其研发重点和策略伙伴关係。

同时，数位化互动的作用持续扩大。宠物饲主现在可以透过线上平台获取兽医资讯、做出购买决策并寻求远距健康咨询，这推动了网路药局和厂商直销管道的兴起。这种转变迫使各利益相关者制定整合的全通路策略，将教育推广、透明的疗效和安全性数据以及简化的购买体验相结合，以建立信任并促进相关人员按时接种疫苗。

此外，社会对宠物预防保健态度的转变以及人们对便利性和个人化照护日益增长的期望正在重塑临床实践。兽医们越来越多地采用基于风险的疫苗通讯协定，利用诊断工具为每隻动物量身定制疫苗接种计划，优化依从性，并优先选择能最大限度减少不利事件的疫苗类型和接种途径。这些因素共同推动了疫苗研发、分发和推荐方式的根本性转变，为价值链上的创新者和服务供应商带来了挑战和机会。

对2025年美国关税对疫苗供应链、生产决策和商业通路经济的累积影响进行全面分析

2025年，美国加征的关税增加了伴侣动物疫苗生态系统中製造商、经销商和临床终端用户的复杂性。这些关税影响了进口原料、成品疫苗、专用设备等的成本结构，改变了供应链决策，并促使企业重新评估生产布局。一些相关人员加快了近岸外包，并实现了供应商组合多元化，以降低贸易相关成本波动带来的风险；而另一些利害关係人则寻求合约对冲，以确保关键投入品的供应。

这些贸易政策调整也影响了各通路的商业规划和定价策略。从国际管道采购疫苗的兽医院和诊所调整了采购週期和供应商条款，以维持可预测的存量基准。线上药局和直接面向製造商的管道则调整了采购组合和物流安排，以确保宠物饲主的收货时间和服务水准。同时，监管合规和海关管制在产品上市和跨境分销的讨论中也变得更加重要。

此外，关税引发的供应链重组促使人们重新关注国内製造能力和官民合作关係，以增强生物製造的韧性。投资者和策略领导者正在权衡建立国内生产能力的益处与相关的资本需求和时限，优先考虑能够灵活调整生产规模的技术。总而言之，这些调整反映了整个行业更广泛的迫切需求，即增强供应链的稳健性，减少对单一供应商的依赖，并使商业模式适应日益加剧的贸易不确定性环境。

可操作的细分市场情报，揭示产品类型、疫苗平台、给药途径和分销管道如何相互交织，从而塑造产品和商业化策略。

细分市场分析揭示了需求驱动因素、临床偏好和管道行为如何因物种、疫苗平台、给药途径和通路而异。就动物物种而言，猫和狗的流行病学和饲养方式存在差异，这会影响疫苗的优先顺序、接种计划和饲主的咨询。犬类疫苗接种策略通常着重于与户外活动和社交互动相关的核心疫苗和生活方式疫苗，而猫的通讯协定则优先考虑与室内/室外环境和多宠物家庭相关的疾病风险。

从疫苗类型来看，灭活疫苗和减毒活病毒疫苗仍然是多种适应症的常用疫苗，其中去活化疫苗进一步细分为裂解细胞和全细胞疫苗，这些差异会影响免疫抗原性和反应原性。 mRNA疫苗和重组疫苗等新型疫苗为更精准地靶向疾病和设计抗原结构提供了契机，从而优化免疫反应并减少不利事件。次单位疫苗疫苗和类毒素疫苗在对抗某些病原体方面仍然发挥着重要作用，因为在这些情况下，目标抗原呈现或毒素中和至关重要。

给药途径是另一个关键的差异化因素，鼻腔或口服黏膜给药方式为肠外肌肉注射或皮下注射提供了一种非侵入性替代方案，并可实现独特的免疫学特性。传统的实体管道，例如药局、兽医诊所和动物医院，以及由网路药局和製造商网站组成的线上管道，都呈现出不同的客户触点和监管考量。了解这些细分维度如何相互交织，对于设计符合相关人员期望和业务实际情况的产品系列、临床指南和通路策略至关重要。

区域策略洞察，揭示不同管理体制、兽医基础设施和饲主行为如何驱动全球市场采取差异化策略

美洲、欧洲、中东和非洲以及亚太地区的区域动态对临床实务规范、法律规范和商业性模式有显着影响。在美洲，兽医基础设施和饲主参与模式支持多元化的分销管道，强大的诊所网路和日益普及的数位化应用增强了预防保健解决方案的推广和零售。相较之下，欧洲、中东和非洲的法规环境和经济状况呈现出复杂多变的特点，因此需要高度区域化的监管策略和灵活的分销模式，以满足已开发兽医市场和新兴细分市场的需求。

亚太地区既快速接受技术创新，又面临兽医服务可近性参差不齐的问题。主要市场的都市化和宠物拥有率的上升推动了对最新疫苗技术的需求，而物流因素和区域供应链则影响产品的供应。在所有地区，对伴侣动物的文化态度、公共卫生重点以及兽医训练标准都会影响疫苗接种通讯协定的建议和接受程度。这些区域差异要求制定打入市场策略、提供针对特定区域的临床证据，并进行能够引起兽医和饲主共鸣的精准宣传宣传活动。

最终，有效的区域规划将流行病学见解与现实的供应和分销模式、监管指导以及相关人员参与相结合，以确保疫苗创新能够以正确的支援材料和服务模式到达正确的市场。

深入的竞争格局和生态系统评估，揭示现有企业、生物技术创新者和服务提供者如何塑造技术采纳和商业化策略。

伴侣动物疫苗市场由成熟的生产者、专业的生技公司和新兴创新者组成。现有企业继续利用其广泛的商业性布局、与兽医专业人士的长期合作关係以及涵盖传统疫苗平台的丰富产品系列。这些优势有助于扩大规模、提升分销信誉、累积深厚的临床经验，并使其能够与兽医网络和机构投资者保持持续的合作关係。

同时，专业公司和生物技术参与企业正专注于平台创新，瞄准高价值适应症，并利用重组抗原和mRNA构建等技术，透过疗效、安全性和上市速度脱颖而出。这些企业通常寻求与受託製造厂商和学术机构建立策略联盟，以加速研发并优化资本配置。大型製造商与灵活创新者之间的伙伴关係日益普遍，有助于将商业性影响力与科学新颖性结合。

价值链上的服务供应商，包括契约製造、诊断公司和数位健康平台，在产品开发、品质保证和客户参与方面发挥关键作用。可扩展的生产能力、低温运输物流和数据驱动型行销等能力，正协助将科学进步转化为临床应用的产品。总体而言，竞争格局有利于那些兼具科学差异化、稳健的生产能力以及对兽医实践动态的深刻理解的公司，从而实现产品在临床医生和饲主中的持续应用。

为领导者提供清晰、优先的策略建议，重点在于平台多元化、供应链弹性、通路优化和临床证据产生。

产业领导者应围绕四个相互关联的行动调整其策略重点：投资平台多元化、增强供应链韧性、优化通路策略以及深化临床合作。优先采用投资组合策略，平衡对成熟的灭活和减毒活产品以及mRNA、重组、次单元和类毒素技术的投资，将使企业能够同时满足当前的临床需求和应对未来的疾病威胁。此外，选择扩充性的生产合作伙伴并考虑区域生产能力，可以降低贸易中断带来的风险，并有助于加快产品上市速度。

同样重要的是改进分销策略，以适应不断变化的消费者行为。除了加强线上通路（例如网路药局和厂商直销平台）外，还应加强与药局、兽医诊所和医院的合作关係，以确保临床应用和治疗的连续性。此外，针对不同给药途径（无论是黏膜给药或肠外给药）调整讯息，并提供可靠的临床证据，可以提高兽医的信心和饲主的接受度。

最后，领导者应投资于有针对性的临床教育和真实世界证据，以支持差异化的产品定位，并为基于风险的疫苗接种通讯协定提供资讯。落实这些建议需要研发、监管、商业和供应链团队之间的协作，才能将策略意图转化为可衡量的应用成果。

采用稳健的混合调查方法，结合主要相关人员访谈、二手证据综合和交叉检验，确保得出可操作且可靠的研究结果。

本报告的调查方法结合了质性访谈、文献综述和严格的交叉检验，以确保分析的平衡性和可靠性。主要见解来自对兽医从业人员、行业高管、研发负责人和分销专家的结构化访谈，从而对临床应用、产品偏好和物流挑战有了切实的观点。这些定性资讯与监管指南、同行评审的科学文献和公开的行业报告等二手资料相结合，为技术和市场趋势提供了背景资讯。

为了提高可靠性，研究结果在多个相关人员群体和地区进行交叉检验，特别关注已开发市场和新兴市场临床实践模式的差异。这种方法强调假设的透明度、资料来源的清晰记录以及对原始研究伦理标准的遵守。分析方法包括趋势图谱绘製、技术成熟度评估和通路路径分析，旨在揭示商业化影响以及相关人员的策略选择。

此调查方法确保研究结果不仅说明，而且具有可操作性，为决策者评估伴侣动物疫苗领域的创新机会、分销选择和投资重点提供了坚实的基础。

简明扼要地总结了决定伴侣动物疫苗领域策略成果的技术、商业性和区域性因素。

本执行摘要总结了影响伴侣动物疫苗发展的关键动态，重点阐述了科学创新、不断变化的饲主期望、不断演变的分销渠道以及地缘政治供应因素之间的相互作用。 mRNA和重组疫苗等技术的成熟，以及灭活疫苗、减毒活病毒疫苗、次单元和类毒素疫苗等传统疫苗平台的持续应用，为研发人员提供了更广泛的选择，以满足尚未满足的临床需求并提高疫苗的安全性。同时，给药途径偏好和分销管道行为的转变，也要求制定协调一致的策略，以确保疫苗的临床应用和病人遵从性。

此外，美洲、欧洲、中东和非洲以及亚太地区的区域差异凸显了与区域监管机构沟通以及采取符合当地文化的策略的重要性。贸易政策调整的累积影响凸显了供应链敏捷性的必要性以及投资区域製造能力的潜力。能够将科学差异化与商业性规模、稳健的业务运营以及与兽医网路和数位管道的深度伙伴关係相结合的企业，将在竞争中脱颖而出。

总之，积极协调研发、生产和商业策略，并投资于临床证据和通路整合的相关人员，将最有能力将创新转化为改善动物健康结果和永续的业务绩效。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • mRNA和下一代疫苗平台在犬猫领域的应用日益广泛
  • 针对多种犬类疾病的联合疫苗的需求日益增长，提高了疫苗的覆盖率。
  • 疫苗输送系统的技术进步，例如无针注射器和贴片；
  • 监管协调和加速核准将加快新型宠物疫苗进入市场的速度。
  • 根据每隻宠物的遗传和生活方式因素制定个人化疫苗接种方案的重要性日益凸显。
  • 扩大辅助性治疗，以提高伴侣动物疫苗的有效性
  • 整合数位健康监测和远端医疗平台以提高疫苗接种率
  • 人们越来越关注疫苗相关不利事件，这推动了更安全佐剂和製剂的研发。
  • 生技公司与兽医诊所建立策略伙伴关係，加速疫苗开发平臺
  • 新兴市场兽医诊所网路的全球扩张提高了动物疫苗的可及性。

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 伴侣动物疫苗市场（依动物种类划分）

  • 猫
  • 狗

9. 伴侣动物疫苗市场（依疫苗类型划分）

  • 惰性
    • 裂解疫苗
    • 全颗粒疫苗
  • 活病毒疫苗
  • mRNA
  • 重组
  • 次单元
  • 类毒素

10. 伴侣动物疫苗市场依给药途径划分

  • 黏膜
    • 鼻腔
    • 口服
  • 肠外
    • 肌肉内注射
    • 皮下

11. 伴侣动物疫苗市场依通路划分

  • 在线的
    • 电子药房
    • 製造商网站
  • 药局
  • 兽医诊所
  • 兽医诊所

12. 各地区伴侣动物疫苗市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

13. 伴侣动物疫苗市场（依组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

14. 各国伴侣动物疫苗市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Elanco Animal Health Incorporated
    • Boehringer Ingelheim International GmbH
    • Ceva Sante Animale SA
    • Virbac SA
    • Vetoquinol SA
    • Dechra Pharmaceuticals PLC
    • Laboratorios Hipra, SA
    • Animalcare Group PLC
    • Esco Healthcare
Product Code: MRR-957C47F94D1F

The Companion Animal Vaccine Market is projected to grow by USD 9.54 billion at a CAGR of 8.47% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 4.97 billion
Estimated Year [2025] USD 5.39 billion
Forecast Year [2032] USD 9.54 billion
CAGR (%) 8.47%

Comprehensive introduction to the evolving companion animal vaccine environment where scientific innovation converges with owner expectations and clinical practice shifts

The companion animal vaccine landscape sits at an intersection of scientific advancement, shifting owner expectations, and evolving clinical practice. Contemporary stakeholders operate in an environment where both preventive care philosophy and therapeutic innovation shape vaccination strategies for cats and dogs, influencing clinic workflows and supply chain dynamics. Veterinary professionals increasingly integrate diagnostic screening, individualized vaccine protocols, and risk-based recommendations into routine care, prompting manufacturers and distributors to reassess product portfolios and communication tactics.

As consumer awareness of animal health grows, pet owners demand clearer evidence of vaccine safety and benefit, while digital channels accelerate access to educational content and purchasing options. Concurrently, research breakthroughs in platform technologies such as mRNA and recombinant systems are expanding the range of antigen targets and enabling improved immunogenicity and manufacturing efficiencies. These developments prompt manufacturers to balance legacy product support for inactivated and live attenuated vaccines with investment in next-generation modalities.

In addition, the route of administration and the distribution landscape influence both product design and commercial strategy. Mucosal vaccines administered nasally or orally present different acceptance profiles compared with parenteral intramuscular or subcutaneous injections, and online channels including e-pharmacies and manufacturer websites are transforming procurement behaviors. Taken together, these dynamics require an integrated approach to product development, regulatory strategy, and market engagement that aligns scientific opportunity with practical adoption pathways.

In-depth overview of the major technological, behavioral, and clinical shifts reshaping how companion animal vaccines are developed, delivered, and adopted

The companion animal vaccine sector is undergoing transformative shifts driven by technological innovation, changing consumer behaviors, and evolving regulatory and clinical paradigms. Advances in vaccine platforms, notably mRNA and recombinant technologies, are opening new possibilities for targeted immunization strategies, shorter development cycles, and adaptable manufacturing processes capable of responding to emergent disease threats. These scientific advancements are redefining product roadmaps and prompting incumbent manufacturers to re-evaluate R&D priorities and strategic partnerships.

Simultaneously, the role of digital engagement continues to expand. Pet owners now access veterinary information, make purchasing decisions, and seek telehealth consultations through online portals, influencing the prominence of e-pharmacies and manufacturer direct-sales channels. This shift compels stakeholders to develop integrated omni-channel strategies that combine educational outreach, transparent efficacy and safety data, and streamlined purchasing experiences to build trust and foster adherence to vaccination schedules.

Moreover, changing societal views on preventive healthcare for pets and rising expectations around convenience and individualized care are reshaping clinical practice. Veterinarians are increasingly employing risk-based vaccination protocols, leveraging diagnostic tools to tailor immunization plans for individual animals, and prioritizing vaccine types and routes that optimize compliance and minimize adverse events. Together, these factors constitute a structural shift in how vaccines are developed, distributed, and recommended, creating both challenges and opportunities for innovators and service providers across the value chain.

Comprehensive analysis of the cumulative repercussions of United States tariff measures in 2025 on supply chains, manufacturing decisions, and commercial channel economics for companion vaccines

In 2025, tariff measures implemented by the United States introduced an added layer of complexity for manufacturers, distributors, and clinical end users within the companion animal vaccine ecosystem. Tariffs influence cost structures across imported raw materials, finished vaccines, and specialized equipment, thereby altering supply chain decisions and encouraging re-evaluation of manufacturing footprints. Some stakeholders accelerated nearshoring and diversified supplier portfolios to mitigate exposure to trade-related cost volatility, while others sought contractual hedges that preserved access to critical inputs.

These trade policy adjustments also impacted commercial planning and pricing strategies across distribution channels. Veterinary hospitals and clinics that source vaccines internationally reevaluated procurement cycles and supplier terms to maintain predictable inventory levels. Online pharmacies and manufacturer direct channels responded by adjusting their sourcing mixes and logistics arrangements to sustain delivery timelines and service levels to pet owners. In parallel, regulatory compliance and customs administration became more salient considerations during product launches and cross-border distribution discussions.

Furthermore, the tariff-driven recalibration of supply chains prompted renewed attention to domestic manufacturing capabilities and public-private partnerships that support biomanufacturing resilience. Investors and strategic leaders began to weigh the benefits of building local capacity against the capital requirements and timeframes involved, prioritizing technologies that offer flexible production scales. Collectively, these adjustments reflect a broader industry imperative to enhance supply chain robustness, reduce single-source dependencies, and align commercial models with an environment of elevated trade uncertainty.

Actionable segmentation intelligence illuminating how animal type, vaccine platform, administration route, and distribution channel intersect to shape product and commercialization strategies

Segmentation insights reveal how demand drivers, clinical preferences, and channel behaviors vary across animal type, vaccine platform, administration route, and distribution pathways. When considering animal type, cats and dogs display distinct epidemiological and husbandry profiles that shape vaccine prioritization, dosing schedules, and owner counseling. Vaccination strategies for dogs often emphasize core and lifestyle vaccines aligned with outdoor exposure and social interactions, whereas feline protocols prioritize disease risks aligned with indoor/outdoor status and multi-cat household dynamics.

Diving into vaccine type, inactivated platforms and live attenuated vaccines remain well-established for a variety of indications, with inactivated formulations further differentiated into split cell and whole cell options that influence immunogenicity and reactogenicity considerations. Emerging modalities such as mRNA and recombinant vaccines are creating opportunities to target diseases with greater precision and to design antigen constructs that optimize immune response while potentially reducing adverse events. Subunit and toxoid vaccines continue to play critical roles for specific pathogens where targeted antigen presentation or neutralization of toxins is essential.

Route of administration is another vital differentiator, with mucosal options delivered nasally or orally offering non-invasive alternatives to parenteral intramuscular and subcutaneous injections and enabling unique immunological profiles. Distribution channel dynamics further influence access and adoption; online channels comprised of e-pharmacies and manufacturer websites, along with more traditional outlets such as pharmacies, veterinary clinics, and veterinary hospitals, present differing customer journeys and regulatory considerations. Understanding how these segmentation axes intersect is essential for designing product portfolios, clinical guidance, and channel strategies that align with stakeholder expectations and operational realities.

Strategic regional insights into how diverse regulatory regimes, veterinary infrastructures, and owner behaviors drive differentiated approaches across global markets

Regional dynamics significantly influence clinical practice norms, regulatory frameworks, and commercial approaches across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, veterinary care infrastructure and owner engagement models support diverse distribution channels, with strong clinic networks and growing digital adoption that enhances outreach and retailing of preventive healthcare solutions. In contrast, Europe, Middle East & Africa exhibits a mosaic of regulatory environments and economic contexts, requiring highly localized regulatory strategies and flexible distribution models that accommodate both advanced veterinary markets and emerging segments.

Asia-Pacific presents a mix of rapid innovation adoption and variable access to veterinary services, where urbanization and rising pet ownership in key markets drive demand for modern vaccine technologies while logistical considerations and regional supply chains influence product availability. Across all regions, cultural attitudes toward companion animals, public health priorities, and veterinary training standards shape how vaccination protocols are recommended and accepted. These regional nuances necessitate tailored market entry strategies, localized clinical evidence packages, and targeted communication campaigns that resonate with veterinarians and pet owners alike.

Ultimately, effective regional planning integrates epidemiological insight with pragmatic supply and distribution models, regulatory navigation, and stakeholder engagement to ensure that vaccine innovations reach the right markets with appropriate supporting materials and service models.

Deep competitive and ecosystem assessment revealing how incumbents, biotech innovators, and service providers shape adoption and commercialization strategies

Competitive dynamics in the companion animal vaccine sector reflect a blend of established incumbents, specialist biotech firms, and emerging innovators. Established manufacturers continue to leverage broad commercial footprints, long-standing relationships with veterinary professionals, and extensive product portfolios that span traditional vaccine platforms. These capabilities support scale, distribution reliability, and deep clinical familiarity, enabling sustained engagement with veterinary networks and institutional buyers.

At the same time, specialist companies and biotech entrants focus on platform innovation, targeting high-value indications and leveraging technologies such as recombinant antigens and mRNA constructs to differentiate on efficacy, safety, and speed-to-market. These players often pursue strategic collaborations with contract manufacturing organizations and academic groups to accelerate development while optimizing capital allocation. Partnerships between large-scale manufacturers and nimble innovators are increasingly common, facilitating combination strategies that pair commercial reach with scientific novelty.

Service providers across the value chain, including contract manufacturers, diagnostic firms, and digital health platforms, play a pivotal role in enabling product development, quality assurance, and customer engagement. Their capabilities in scalable manufacturing, cold chain logistics, and data-driven marketing help translate scientific advances into clinically adopted products. Overall, the competitive landscape favors organizations that combine scientific differentiation, manufacturing resilience, and a deep understanding of veterinary practice dynamics to achieve sustained adoption among clinicians and pet owners.

Clear and prioritized strategic recommendations for leaders focused on platform diversification, supply resilience, channel optimization, and clinical evidence generation

Industry leaders should align strategic priorities around four interconnected actions: invest in platform diversification, fortify supply chain resilience, optimize channel strategies, and deepen clinical engagement. Prioritizing a portfolio approach that balances established inactivated and live attenuated products with investments in mRNA, recombinant, subunit, and toxoid technologies will allow organizations to respond to both current clinical needs and future disease threats. Concurrently, selecting scalable manufacturing partners and considering regional production capabilities can reduce exposure to trade disruptions and support faster market responsiveness.

Equally important is the refinement of distribution strategies to reflect evolving purchaser behaviors. Strengthening digital channels such as e-pharmacies and manufacturer direct-sales platforms should be complemented by reinforced relationships with pharmacies, veterinary clinics, and hospitals to ensure clinical adoption and continuity of care. In addition, tailoring messaging to emphasize route-of-administration benefits, whether mucosal or parenteral, and providing robust clinical evidence will improve veterinarian confidence and owner acceptance.

Finally, leaders should invest in targeted clinical education and real-world evidence generation that supports differentiated product positioning and informs risk-based vaccination protocols. Executing these recommendations requires cross-functional coordination across R&D, regulatory, commercial, and supply chain teams to translate strategic intent into measurable adoption outcomes.

Robust mixed-method methodology combining primary stakeholder interviews, secondary evidence synthesis, and cross-validation to ensure actionable and credible insights

The research methodology underpinning this report combines primary qualitative interviews, secondary literature synthesis, and rigorous cross-validation to ensure balanced analysis and credibility. Primary insights were obtained through structured interviews with veterinary practitioners, senior industry executives, R&D leaders, and distribution specialists, providing grounded perspectives on clinical adoption, product preferences, and logistical challenges. These qualitative inputs were synthesized with secondary sources that include regulatory guidance, peer-reviewed scientific literature, and publicly available industry reports to contextualize technological and market trends.

To enhance reliability, findings were cross-validated across multiple stakeholder groups and geographic contexts, with particular attention to differences in clinical practice patterns between developed and emerging veterinary markets. The approach emphasizes transparency in assumptions, clear documentation of data provenance, and adherence to ethical standards in primary research engagements. Analytical methods include trend mapping, technology readiness assessment, and channel pathway analysis to illuminate commercialization implications and strategic options for stakeholders.

This methodology ensures that insights are not only descriptive but also actionable, offering decision-makers a robust foundation to evaluate innovation opportunities, distribution choices, and investment priorities within the companion animal vaccine landscape.

Concise conclusion synthesizing technological, commercial, and regional imperatives that determine strategic outcomes in the companion animal vaccine sector

This executive summary synthesizes the essential dynamics shaping companion animal vaccines, underscoring the interplay of scientific innovation, changing owner expectations, distribution evolution, and geopolitical supply considerations. The maturation of technologies such as mRNA and recombinant vaccines, coupled with enduring roles for inactivated, live attenuated, subunit, and toxoid platforms, provides a broad palette for developers to address unmet clinical needs and improve safety profiles. Parallel shifts in route-of-administration preferences and distribution channel behaviors require coordinated strategies to ensure clinical adoption and owner adherence.

Moreover, regional differences across the Americas, Europe, Middle East & Africa, and Asia-Pacific emphasize the importance of localized regulatory navigation and culturally attuned engagement. The cumulative impact of trade policy adjustments highlighted the need for supply chain agility and potential investments in regional manufacturing capabilities. Competitive success will favor organizations that can blend scientific differentiation with commercial scale, resilient operations, and deep partnerships across veterinary networks and digital channels.

In conclusion, stakeholders that proactively align R&D, manufacturing, and commercial strategies while investing in clinical evidence and channel integration will be best positioned to translate innovation into improved animal health outcomes and sustainable business performance.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Rising adoption of mRNA and next-generation vaccine platforms for dogs and cats
  • 5.2. Increasing demand for combination vaccines targeting multiple canine diseases to improve coverage
  • 5.3. Technological advancements in vaccine delivery systems such as needle-free injectors and patches
  • 5.4. Regulatory harmonization and fast-track approvals enabling quicker market entry for novel pet vaccines
  • 5.5. Growing emphasis on personalized vaccination schedules based on individual pet genetics and lifestyle factors
  • 5.6. Expansion of probiotic and immunomodulator adjunct therapies to enhance vaccine efficacy in companion animals
  • 5.7. Integration of digital health monitoring and telemedicine platforms to boost vaccine compliance rates
  • 5.8. Rising concerns over vaccine-associated adverse events driving development of safer adjuvants and formulations
  • 5.9. Strategic collaborations between biotech firms and veterinary clinics to accelerate vaccine R&D pipelines
  • 5.10. Global expansion of veterinary clinic networks in emerging markets increasing access to animal vaccines

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Companion Animal Vaccine Market, by Animal Type

  • 8.1. Cats
  • 8.2. Dogs

9. Companion Animal Vaccine Market, by Vaccine Type

  • 9.1. Inactivated
    • 9.1.1. Split Cell
    • 9.1.2. Whole Cell
  • 9.2. Live Attenuated
  • 9.3. mRNA
  • 9.4. Recombinant
  • 9.5. Subunit
  • 9.6. Toxoid

10. Companion Animal Vaccine Market, by Route Of Administration

  • 10.1. Mucosal
    • 10.1.1. Nasal
    • 10.1.2. Oral
  • 10.2. Parenteral
    • 10.2.1. Intramuscular
    • 10.2.2. Subcutaneous

11. Companion Animal Vaccine Market, by Distribution Channel

  • 11.1. Online
    • 11.1.1. E Pharmacies
    • 11.1.2. Manufacturer Websites
  • 11.2. Pharmacies
  • 11.3. Veterinary Clinics
  • 11.4. Veterinary Hospitals

12. Companion Animal Vaccine Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Companion Animal Vaccine Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Companion Animal Vaccine Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Zoetis Inc.
    • 15.3.2. Merck & Co., Inc.
    • 15.3.3. Elanco Animal Health Incorporated
    • 15.3.4. Boehringer Ingelheim International GmbH
    • 15.3.5. Ceva Sante Animale S.A.
    • 15.3.6. Virbac S.A.
    • 15.3.7. Vetoquinol S.A.
    • 15.3.8. Dechra Pharmaceuticals PLC
    • 15.3.9. Laboratorios Hipra, S.A.
    • 15.3.10. Animalcare Group PLC
    • 15.3.11. Esco Healthcare

LIST OF FIGURES

  • FIGURE 1. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. COMPANION ANIMAL VACCINE MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. COMPANION ANIMAL VACCINE MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. COMPANION ANIMAL VACCINE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY CATS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DOGS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SPLIT CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY WHOLE CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY LIVE ATTENUATED, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MRNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY RECOMBINANT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBUNIT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY TOXOID, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY NASAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ORAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY INTRAMUSCULAR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY E PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY MANUFACTURER WEBSITES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY PHARMACIES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY VETERINARY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 156. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 157. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 158. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 159. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 162. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 163. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 164. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 165. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 166. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 167. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 168. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 169. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 170. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 171. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 172. AMERICAS COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 173. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 174. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 175. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 176. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 177. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 178. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 179. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 180. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 181. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 182. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 183. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 184. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 185. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 186. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 187. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 188. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 189. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 190. NORTH AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 191. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 198. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 199. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 200. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 201. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 202. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 203. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 204. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 205. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 206. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 207. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 208. LATIN AMERICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 209. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 210. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 211. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 212. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 213. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 214. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 215. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 216. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 217. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 218. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 219. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 220. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 221. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 222. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 223. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 224. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 225. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 226. EUROPE, MIDDLE EAST & AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 227. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 230. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 231. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 232. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 233. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 234. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 245. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 246. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 247. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 248. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 249. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 250. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 251. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 252. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 253. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 254. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 255. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 256. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 257. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 258. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 259. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 260. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 261. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 262. MIDDLE EAST COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 263. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 270. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 271. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 272. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 273. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 274. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 275. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 276. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 277. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 278. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 279. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 280. AFRICA COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 281. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 282. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 283. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 284. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 285. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 286. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 287. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 288. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 289. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 290. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 291. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 292. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 293. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 294. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 295. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 296. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 297. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 298. ASIA-PACIFIC COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 299. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 300. GLOBAL COMPANION ANIMAL VACCINE MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 301. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 302. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 303. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2018-2024 (USD MILLION)
  • TABLE 304. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ANIMAL TYPE, 2025-2032 (USD MILLION)
  • TABLE 305. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2018-2024 (USD MILLION)
  • TABLE 306. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY VACCINE TYPE, 2025-2032 (USD MILLION)
  • TABLE 307. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2018-2024 (USD MILLION)
  • TABLE 308. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY INACTIVATED, 2025-2032 (USD MILLION)
  • TABLE 309. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2024 (USD MILLION)
  • TABLE 310. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2025-2032 (USD MILLION)
  • TABLE 311. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2018-2024 (USD MILLION)
  • TABLE 312. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY MUCOSAL, 2025-2032 (USD MILLION)
  • TABLE 313. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2018-2024 (USD MILLION)
  • TABLE 314. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY PARENTERAL, 2025-2032 (USD MILLION)
  • TABLE 315. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
  • TABLE 316. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2032 (USD MILLION)
  • TABLE 317. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2018-2024 (USD MILLION)
  • TABLE 318. ASEAN COMPANION ANIMAL VACCINE MARKET SIZE, BY ONLINE, 2025-2032 (USD MILLION)
  • TABLE 319. GCC COMPANION ANIMAL VACCINE MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GCC COM